> ## Documentation Index
> Fetch the complete documentation index at: https://mso.getlemma.com/llms.txt
> Use this file to discover all available pages before exploring further.

# Where the profit lives: MSO economics and fee structures

> The MSO's fee income is the investable earnings stream. How each fee structure allocates margin, why groups migrate from fixed to cost-plus, and the permanent tension between FMV and capturing the economics.

In an MSO-PC group, **the MSO's fee income is the investable earnings stream**, because capital cannot own the PC. That single fact means the management fee structure does not merely price a service. It determines where profit shows up, and therefore what an investor is buying.

## The core model

```mermaid theme={null}
graph LR
    A[Patient care delivered] --> B[Payer + patient revenue<br/>lands in the PC]
    B --> C[PC pays clinical<br/>compensation and<br/>direct expenses]
    C --> D[PC pays the<br/>management fee]
    D --> E[MSO revenue]
    E --> F[MSO pays<br/>non-clinical costs]
    F --> G[MSO profit<br/>= what investors own]
    C --> H[PC residual<br/>≈ break-even by design]
```

Read the two endpoints. **MSO profit is ownable. PC residual is not** — it belongs to a clinician who typically does not take distributions of it, and no investor can hold equity in the PC.

So the fee is the valve. It determines how much of the enterprise's economics lands on the ownable side.

## How each structure allocates margin

| Structure            | MSO economics                                | PC economics                                                      | Investor view                               | Regulatory view                                |
| -------------------- | -------------------------------------------- | ----------------------------------------------------------------- | ------------------------------------------- | ---------------------------------------------- |
| **Fixed fee**        | Predictable, doesn't scale with the business | Absorbs all volatility, residual profit *or* loss stays in the PC | Weak: earnings don't grow with the practice | Cleanest, plainly a price for services         |
| **Cost-plus markup** | A defined margin on a growing cost base      | More stable; costs are predictable                                | Strong: recurring, scaling, FMV-anchored    | Good, tethered to services actually provided   |
| **% of collections** | Scales directly with practice performance    | Residual varies with the percentage                               | Strongest: pure revenue share               | Riskiest, structurally resembles fee-splitting |

### Fixed fee

A flat monthly amount. Simple, easy to FMV-support when the MSO's service scope is thin, and it gives a new PC predictable costs before revenue stabilizes.

Its weakness as the business grows: **the MSO's earnings don't move.** A practice that doubles its revenue produces the same fee, and the incremental profit strands in the PC, where no investor can reach it. A group scaling on a fixed fee ends up with growing PC surpluses and flat MSO earnings, which is precisely backwards from what capital is underwriting.

### Cost-plus with a markup

The MSO charges its actual costs of providing services plus a stated markup, commonly expressed as cost plus a percentage.

This is the structure most mature groups converge on, and the reason is that it satisfies both audiences at once:

* **For regulators**, the fee is tethered to services actually provided, at a cost that can be documented, with a margin that can be benchmarked. It is a price, not a profit share.
* **For investors**, MSO profit becomes a **defined, recurring margin on a growing cost base**, a real earnings stream that scales as the group scales, rather than an arbitrary number reset by negotiation.

As the MSO absorbs more services — more staff, more technology, more locations supported — its cost base grows, and the markup grows with it.

### Percentage of collections

The MSO takes a stated percentage of practice revenue. Maximum alignment with practice performance, and maximum fee-splitting exposure, because it is structurally identical to sharing professional fees with a non-licensee.

Viable in permissive states. Materially risky in New York and Florida, among others. See [Fee-splitting rules](/concepts/model/fee-splitting).

## The typical arc

```mermaid theme={null}
graph LR
    A["Launch<br/>Fixed monthly fee"] --> B["Scale<br/>Cost-plus markup"]
    B --> C["Mature<br/>% of collections,<br/>where lawful"]
```

Almost every group re-papers the fee as it matures. **Start fixed** because it is simple and defensible when the MSO does little. **Migrate to cost-plus** as the MSO absorbs real services and its cost base becomes measurable — this is the transition that matters most, because it is where MSO earnings start to scale. **Percentage only where state law tolerates it**, and many groups never get there.

The mechanics of the transition — amendment versus restated MSA, board consents, a refreshed FMV study before the new fee takes effect, per-state re-check — are in [Evolve the fee structure](/guides/agreements/evolve-the-fee-structure).

## The permanent tension

Stated plainly, because it does not resolve:

> **The fee must simultaneously be fair market value for services rendered (the regulator's lens) and capture the enterprise's economics (the investor's lens).**

These pull in opposite directions. FMV asks *what would an unrelated party charge for exactly these services?* Investors ask *how much of this business's profit lands where we own it?*

Structures that resolve the tension by ignoring the first side, sweeping essentially all PC profit regardless of services rendered, are the ones that get recharacterized. The fee that takes 100% of practice surplus is not a price; it is ownership by contract, which is the CPOM allegation.

Structures that ignore the second side leave capital unable to underwrite the business.

The workable answer is **cost-plus with a defensible markup**: the fee grows with the services actually provided, the margin is benchmarkable, and the growth is real rather than extracted.

## The PC-side corollary

A well-run PC ends up **near break-even** after clinical compensation and the management fee. That is the design, not a failure.

But the corollary matters:

**A persistently loss-making PC is a signal, not a rounding error.** If a PC cannot pay its management fee out of its own collections after clinical compensation, not during the ramp, but steadily, one of two things is true:

1. **The fee is too high for what this PC can support**, which is an FMV problem as well as an economic one. A fee no arm's-length practice could pay is a fee that looks like profit extraction.
2. **The PC's unit economics don't work** — payer mix, rates, or volume — and the fee structure is masking it.

Either way, propping up negative PC equity with undocumented intercompany transfers converts an operating problem into a structural one. See [Intercompany money movement](/concepts/banking/intercompany-money-movement).

Run a **fee-coverage check** per PC, monthly: can this entity pay its fee from its own collections?

## What this means for how you model

Three implications for financial planning in an MSO-PC group:

**Model the MSO separately.** Consolidated revenue includes intercompany fee dollars counted twice, and it is not what investors buy. Build an MSO-standalone P\&L from day one.

**Model each PC's fee coverage.** Per-entity unit economics — revenue, clinical comp, fee paid, residual — tell you which markets work.

**Model the transition.** If you plan to move from fixed to cost-plus in year two, model both, because the MSO's earnings profile changes materially and that is the number a raise is priced on.

See [How investors read MSO-PC financials](/concepts/finance/how-investors-read-mso-pc-financials).


## Related topics

- [Set the management fee](/guides/agreements/set-the-management-fee.md)
- [Evolve the fee structure (fixed → cost-plus → percentage)](/guides/agreements/evolve-the-fee-structure.md)
- [Produce investor-grade financial reporting](/guides/banking/produce-investor-reporting.md)
- [Fee-splitting rules, explained](/concepts/model/fee-splitting.md)
- [How investors read MSO-PC financials](/concepts/finance/how-investors-read-mso-pc-financials.md)
- [Intercompany money movement](/concepts/banking/intercompany-money-movement.md)
- [MSA clause anatomy](/reference/legal/msa-clause-anatomy.md)